nach oben

Virchows Archiv

Erschienen in:

19.04.2018 | Original Article

The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer

verfasst von: Jens Neumann, Volker Heinemann, Jutta Engel, Thomas Kirchner, Sebastian Stintzing

Erschienen in: Virchows Archiv | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Loss of CDX2 expression has been proposed to be a prognostic biomarker in colorectal cancer (CRC) correlating with shorter overall (OS) and progression-free survival (PFS). Since metastatic disease, mismatch repair (MMR) deficiency, and the mutational status of BRAF are considered to be important prognostic determinants in CRC, the present study aimed to analyze CDX2 expression in correlation with these parameters. Immunohistochemistry for CDX2, hMLH1, and hMSH2 was applied to a study cohort of 503 CRC specimens (FIRE-3) and a matched case-control collection of 50 right-sided CRC specimens with synchronous distant metastases and 50 right-sided CRCs without distant metastases. Furthermore, the mutational status of BRAF gene was analyzed utilizing pyrosequencing. CDX2 expression significantly correlates with reduced OS (p = 0.008) within the study population. In both cohorts, a significant correlation of CDX2 expression and MMR deficiency as well as the presence of a BRAF mutation (each p > 0.001) was observed, whereas no correlation of CDX2 expression and synchronous metastasis could be obtained. In the case-control study, only patients with proficient MMR status showed a correlation of CDX2 loss and synchronous metastasis, whereas in patients with deficient MMR status and CDX2 loss, no distant metastases at the time of diagnosis were found (p = 0.003). We could demonstrate that the reduced OS of CDX2-negative CRC patients is not caused by higher rates of distant metastases. Furthermore, our data indicate that the prognostic impact of CDX2 depends on the MMR status and the BRAF mutational status of the tumors. Thus, it could be concluded that CDX2 is not an independent prognostic biomarker in CRC.

Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S (2009) Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 15:4665–4673. https://doi.org/10.1158/1078-0432.CCR-09-0401 CrossRefPubMedPubMedCentral

Bonhomme C, Duluc I, Martin E, Chawengsaksophak K, Chenard MP, Kedinger M, Beck F, Freund JN, Domon-Dell C (2003) The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development. Gut 52:1465–1471CrossRefPubMedPubMedCentral

Bosman F, Carneiro F, Hruban R, Theise N (2010) WHO classification of tumours of the digestive system. International Agency for Research on Cancer (IARC), Lyon

Brierley J, Gospodarowicz M, Wittekind C (2017) TNM classification of malignant tumours, 8th edn. John Wiley & Sons, Oxford

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgo E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF (2016) CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med 374:211–222. https://doi.org/10.1056/NEJMoa1506597 CrossRefPubMedPubMedCentral

Dawson H, Galvan JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A, Zlobec I (2014) Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer 134:2342–2351. https://doi.org/10.1002/ijc.28564 CrossRefPubMed

Dawson H, Koelzer VH, Lukesch AC, Mallaev M, Inderbitzin D, Lugli A, Zlobec I (2013) Loss of Cdx2 expression in primary tumors and lymph node metastases is specific for mismatch repair-deficiency in colorectal cancer. Front Oncol 3:265. https://doi.org/10.3389/fonc.2013.00265 CrossRefPubMedPubMedCentral

Desch CE, Benson AB 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ, American Society of Clinical O (2005) Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23:8512–8519. https://doi.org/10.1200/JCO.2005.04.0063 CrossRefPubMed

Gkekas I, Novotny J, Pecen L, Strigard K, Palmqvist R, Gunnarsson U (2017) Microsatellite instability as a prognostic factor in stage II colon cancer patients, a meta-analysis of published literature. Anticancer Res 37:6563–6574. https://doi.org/10.21873/anticanres.12113 PubMedCrossRef

10.

Gross I, Duluc I, Benameur T, Calon A, Martin E, Brabletz T, Kedinger M, Domon-Dell C, Freund JN (2008) The intestine-specific homeobox gene Cdx2 decreases mobility and antagonizes dissemination of colon cancer cells. Oncogene 27:107–115. https://doi.org/10.1038/sj.onc.1210601 CrossRefPubMed

11.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Muller S, Link H, Niederle N, Rost A, Hoffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075. https://doi.org/10.1016/S1470-2045(14)70330-4 CrossRefPubMed

12.

Herr R, Brummer T (2015) BRAF inhibitors in colorectal cancer: toward a differentiation therapy? Mol Cell Oncol 2:e1002709. https://doi.org/10.1080/23723556.2014.1002709 CrossRefPubMedPubMedCentral

13.

Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, Loda M, Appelman HD, Cho KR, Fearon ER (2001) Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol 159:2239–2248. https://doi.org/10.1016/S0002-9440(10)63074-X CrossRefPubMedPubMedCentral

14.

Hong KD, Lee D, Lee Y, Lee SI, Moon HY (2013) Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. Am Surg 79:353–360PubMed

15.

Hryniuk A, Grainger S, Savory JG, Lohnes D (2014) Cdx1 and Cdx2 function as tumor suppressors. J Biol Chem 289:33343–33354. https://doi.org/10.1074/jbc.M114.583823 CrossRefPubMedPubMedCentral

16.

Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ (2016) Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer 115:25–33. https://doi.org/10.1038/bjc.2016.161 CrossRefPubMedPubMedCentral

17.

Landau MS, Kuan SF, Chiosea S, Pai RK (2014) BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression. Hum Pathol 45:1704–1712. https://doi.org/10.1016/j.humpath.2014.04.008 CrossRefPubMed

18.

Lugli A, Tzankov A, Zlobec I, Terracciano LM (2008) Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol 21:1403–1412. https://doi.org/10.1038/modpathol.2008.117 CrossRefPubMed

19.

Malesci A, Laghi L, Bianchi P, Delconte G, Randolph A, Torri V, Carnaghi C, Doci R, Rosati R, Montorsi M, Roncalli M, Gennari L, Santoro A (2007) Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 13:3831–3839. https://doi.org/10.1158/1078-0432.CCR-07-0366 CrossRefPubMed

20.

O'Brien MJ, Zhao Q, Yang S (2015) Colorectal serrated pathway cancers and precursors. Histopathology 66:49–65. https://doi.org/10.1111/his.12564 CrossRefPubMed

21.

Olsen J, Eiholm S, Kirkeby LT, Espersen ML, Jess P, Gogenur I, Olsen J, Troelsen JT (2016) CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer. Exp Mol Pathol 100:59–66. https://doi.org/10.1016/j.yexmp.2015.11.009 CrossRefPubMed

22.

Olsen J, Espersen ML, Jess P, Kirkeby LT, Troelsen JT (2014) The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review. Surg Oncol 23:167–176. https://doi.org/10.1016/j.suronc.2014.07.003 CrossRefPubMed

23.

Silberg DG, Swain GP, Suh ER, Traber PG (2000) Cdx1 and cdx2 expression during intestinal development. Gastroenterology 119:961–971CrossRefPubMed

24.

Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis VL, Vaccaro GM, Wong MH, Mayo SC (2017) Colorectal cancer liver metastasis: evolving paradigms and future directions. Cell Mol Gastroenterol Hepatol 3:163–173. https://doi.org/10.1016/j.jcmgh.2017.01.006 CrossRefPubMedPubMedCentral

Titel: The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer
verfasst von: Jens Neumann
Volker Heinemann
Jutta Engel
Thomas Kirchner
Sebastian Stintzing
Publikationsdatum: 19.04.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 2/2018
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2360-y

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Springer Medizin

The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

A case of multiple familial trichoepitheliomas responding to treatment with the Hedgehog signaling pathway inhibitor vismodegib

Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma

Genetic zygosity of mature ovarian teratomas, struma ovarii, and ovarian carcinoids

Neuroendocrine tumor of the pancreas with rhabdoid feature

Duodenal histological features in suspected non-celiac gluten sensitivity: new insights into a still undefined condition

Book Review—Diagnostic immunohistochemistry, 5th edition

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien